Enhancing Cancer Patient Outcomes using Theranostic Nanomedicine: Advances, Challenges, and Future Prospects.

Abstract

Theranostic nanomedicine integrates diagnostic and therapeutic functions into a single nanoparticle, allowing clinicians to image a tumor and treat it with the same agent. The logic is simple: instead of administering separate compounds to patients for imaging and treatment, both functions are delivered concurrently. Nanoparticles reach tumor tissue mainly through the EPR effect; leaky vasculature and poor lymphatic drainage cause passive accumulation. Attaching ligands for receptors overexpressed on tumor cells adds a second layer of selectivity. Liposomes, dendrimers, polymeric micelles, and metal nanoparticles have all been adapted for drug-imaging combinations, each with different loading and surface modification options. Protein corona remains a frustrating obstacle. Serum proteins adsorb onto nanoparticle surfaces and throw off targeting, which has pushed groups toward more elaborate designs. D-type peptide-modified nanoparticles withstand enzymatic degradation better than standard L-type versions; oncolytic peptide-based systems have also shown immune-activating effects alongside direct cytotoxicity. Stimulus-responsive release pH, redox, or light-triggered continues to attract attention as a way to limit off-target exposure. However, most programmes fail to progress beyond clinical translation. Tumor heterogeneity means a nanoparticle optimized for one patient's receptor profile may be unremarkable in another patient's profile. Regulators have not agreed on how to classify combination nano-diagnostic-therapeutic products, so approval pathways are unclear. Large-scale synthesis, reproducible manufacturing, and harmonized evaluation guidelines all remain to be established before clinical translation can proceed.